ANRO
Alto NeuroscienceยทNYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ANRO Profile
Alto Neuroscience, Inc.
A clinical-stage biopharmaceutical company in California
Pharmaceutical
03/25/2019
02/02/2024
New York Stock Exchange
76
12-31
Common stock
650 Castro Street, Suite 450 Mountain View, CA 94041
--
Alto Neuroscience, Inc., was incorporated in Delaware on March 25, 2019. The company is headquartered in Los Altos, California. The company is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and efficient treatment options. Building on more than a decade of research by its founder, Dr. Amit Etkin, the company's goal is to gain insight into brain function and more effectively match patients with the right drugs by using treatments that target specific patient groups. The company's current product line includes five clinical-stage assets, initially targeting major depression (MDD) and schizophrenia populations with independent brain-based biomarkers. Each of the company's clinical stage product candidates has been evaluated through at least initial Phase 1 clinical trials and has been observed to be well tolerated. The company's most advanced programs, including two product candidates evaluated in ongoing late-stage (2b or later) trials, are supported by prospective repeating evidence of clinical activity in the biomarker signature population.
